Editorial: The unaffordable cost of M&A-driven drug prices

Editorial: The unaffordable cost of M&A-driven drug prices

By Merrill Goozner  |  August 27, 2016

There still is no connection between the price of new drugs and the cost of discovering and developing them, even though the pharmaceutical industry has argued for years that such a link was the primary justification for high prices.

Pfizer beats Street 2Q forecasts despite big drop in profit

By Associated Press  |  August 02, 2016

Rising sales of Pfizer's key new medicines and prospects that more drugs will be approved soon have analysts speculating the biggest U.S. drugmaker won't break up after all. Its adjusted earnings amounted to 64 cents per share, two cents better than analysts estimated.

Making HSAs work for chronic care

Making HSAs work for chronic care

By Bob Herman  |  July 30, 2016

Early last month, U.S. Reps. Diane Black (R-Tenn.) and Earl Blumenauer (D-Ore.)—both of whom sit on the House Ways and Means Committee's Health Subcommittee—introduced a bill that would change how the federal tax code treats high-deductible health plans that are paired with tax-exempt...

Supply chain firms to discuss effects of UDI mandate

By Adam Rubenfire  |  July 23, 2016

A federal mandate to use unique device identifiers offers an opportunity to reduce the risk of patients being harmed by products, but the UDI system, which is being implemented over the next four years by the Food and Drug Administration, means a lot of changes— especially for the...

Pfizer tops Q1 forecasts on higher sales, lower taxes

By Associated Press  |  May 03, 2016

Pfizer easily beat Wall Street expectations as the biggest U.S. drugmaker's first-quarter net income jumped 27% due to higher sales, a lower tax bill and some one-time gains. The company raised its 2016 financial forecasts, citing the strong quarter and an improved business outlook.

Allergan, Pfizer call off proposed $160B merger

By Associated Press  |  April 06, 2016

The biggest U.S.-based drugmaker, Pfizer, will stay put thanks to aggressive new Treasury Department rules that succeeded in discouraging Pfizer's plan to acquire rival Allergan and move to Ireland—on paper—to reduce its tax bill.

FDA approves biosimilar of J&J's money maker Remicade

By Associated Press  |  April 05, 2016

The approval of Inflectra Tuesday is only the second time that the FDA has approved a quasi-generic version of a biotech drug for the U.S. market. Remicade, a medicine for inflammatory diseases, had $6.56 billion in sales last year.

Allergan shares tumble on new tax inversion rules

By Associated Press  |  April 05, 2016

Allergan's stock is down nearly 20% in pre-market Tuesday trading after the U.S. announced an aggressive push in its campaign to shut down so-called tax inversions by American companies.

Pfizer adds $784.6M charge for Protonix deal to Q4 results

By Associated Press  |  February 16, 2016

Drugmaker Pfizer swung to a fourth-quarter financial loss, instead of a modest profit, as a result of a just-announced charge to settle a long-running federal case over reimbursements for its former blockbuster heartburn pill.

Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.